Outcome reporting from protocols of clinical trials of Coronavirus Disease 2019 (COVID-19): a review

Ruijin Qiu, Xuxu Wei, Mengzhu Zhao, Changming Zhong, Chen Zhao, Jiayuan Hu, Min Li, Ya Huang, Songjie Han, Tianmai He, Jing Chen, Hongcai Shang
doi: https://doi.org/10.1101/2020.03.04.20031401

Abstract

Objectives To examine heterogeneity of outcomes in protocols of clinical trials of Coronavirus Disease 2019 (COVID-19) and to identify outcomes for prioritization in developing a core outcome set (COS) in this field.

Design This study is a review.

Data sources Databases of ICMJE-accepted clinical trial registry platform were searched on February 14, 2020.

Eligibility Criteria Randomized controlled trials (RCTs) and non-RCTs of COVID-19 were considered. Conditions of patients include common type, severe type or critical type. Interventions include traditional Chinese medicine (TCM) and Western medicine. We excluded trials that for discharged patients, psychological intervention and complications of COVID-19.

Data extraction and synthesis The general information and outcomes, outcome measurement instruments and measurement times were extracted. The results were analysed by descriptive analysis.

Results 19 registry platforms were searched. A total of 97 protocols were included from 160 protocols. For protocols of TCM clinical trials, 76 outcomes from 16 outcome domains were reported, and almost half (34/76, 44.74%) of outcomes were reported only once; the most frequently reported outcome was time of SARS-CoV-2 RNA turns to negative. 27 (27/76, 35.53%) outcomes were provided one or more outcome measurement instruments. 10 outcomes were provided one or more measurement time frame. For protocols of western medicine clinical trials, 126 outcomes from 17 outcome domains were reported; almost half (62/126, 49.21%) of outcomes were reported only once; the most frequently reported outcome was proportion of patients with negative SARS-CoV-2. 27 outcomes were provided one or more outcome measurement instruments. 40 (40/126, 31.75%) outcomes were provided one or more measurement time frame.

Conclusion Outcome reporting in protocols of clinical trials of COVID-19 is inconsistent. Thus, developing a core outcome set is necessary.

Strengths and limitations of this study

  • 1. This review is the first to describe variation in outcomes, outcome measurement instruments and outcome measurement time reporting in clinical trials for Coronavirus Disease 2019 (COVID-19).

  • 2. All the database of ICMJE-accepted clinical trial registry platform were searched, and randomized controlled trials and observational studies were considered.

  • 4. The aim of this review was to provide a list of outcomes for clinical trials of COVID-19, both interventions of Traditional Chinese Medicine and western medicine were considered.

  • 5. When the searching was conducted, no clinical trials were registered by countries out of China, so all of included protocols were from China.

INTRODUCTION

Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection occurred in Wuhan, Hubei Province from December 2019, the disease, which was named as Coronavirus Disease 2019 (COVID-19) by World Health Organization (WHO) on February 12, 2020. According to the website of National Health Commission of the People’s Republic of China (NHC-PRC), 77,658 confirmed cases have been reported from all areas of China until 0 o’clock, February 25, 2020. 27,323 cured patients discharged, 2,663 patients died [1]. On the website of WHO showed that 2559 confirmed cases have been reported in 33 countries out of China, 34 patients died at 10AM CET, February 25 2020 [2].

However, there is still no specific medicine for COVID-19 now. In China, the government encourages traditional Chinese medicine (herbal medicine, moxibustion, Baduanjin, etc.) to take an important role in clinical practice. The NHC-PRC and National Administration of Traditional Chinese Medicine (NATCM) have released the Version 6.0 of Diagnosis and Treatment Guideline for COVID-19 (informal version) on February 18, 2020 [3]. The guideline recommended general therapy methods, such as oxygen support, or trying to use alpha-interferon, Lopinavir/Ritonavir, Ribavirin, Chloroquine phosphate, Abidol, etc. For severe and critical type of disease, high flow nasal catheter oxygen therapy, invasive or non-invasive mechanical ventilation, extracorporeal membrane oxygenation (ECMO), plasma of survivors, glucocorticoid, plasma exchange or according to the patients’ situation. The guideline also recommended TCM therapy methods, including herbal medicine formulas and proprietary Chinese medicine according to TCM syndromes, which are analyzed by clinical symptoms and signs through four methods of diagnosis: inspection, auscultation and olfaction, interrogation, and palpation.

At the same time, an increasing number of clinical trials are conducting. After searching some protocols of clinical trials from Chinese Clinical Trial Registry (ChiTCR) and ClinicalTrials.gov, we found that different researchers chose different outcomes. It is very important for clinical trials to provide evidence in treating COVID-19. However, the heterogeneity of outcomes make it impossible to conduct meta-analysis in the future, which may reduce the value of clinical trials and improve waste.

We are going to develop a core outcome set (COS) for clinical trials of COVID-19. The study have been registered in Core Outcome Measures in Effectiveness Trials (COMET) database [4]. The first clinical trial of COVID-19 was registered on January 23, 2020 [5]. When we registered the COS study, there were about 50 clinical trials registered [4]. On February 25, 2020, the number of registered trials increased to 297. Before we finish the COS, we believe that it is very important to draw researchers’ attention to concern about outcomes in their research. So we conducted a review of outcome reporting from registered clinical trials of COVID-19. Because TCM and western medicine take the same role in the treatment of COVID-19 in China, so the review includes both interventions.

METHODS

Search strategy

All the databases of ICMJE-accepted clinical trial registry platform [6] were considered. Search terms for ChiCTR included “COVID-19”, “2019-novel Corona Virus (2019-nCoV)”, “Novel Coronavirus Pneumonia (NCP)”, “Severe Acute Respiratory Infection (SARI)”, “Severe Acute Respiratory Syndrome - Corona Virus-2 (SARS-CoV-2)”. Search terms for Netherlands National Trial Register (NTR) included “nCoV”, “Coronavirus”, “SARS”, “SARI”, “NCP”, “COVID”. Search terms for other databases included “2019-nCoV OR Novel Coronavirus OR New Coronavirus OR SARS-CoV-2 OR SARI OR NCP OR Novel Coronavirus Pneumonia OR COVID-19 OR Wuhan pneumonia”. The searching conducted on n February 14, 2020.

Inclusion criteria

  1. The population should include conformed patients of COVID-19.

  2. Patients’ conditions include common type, severe type or critical type.

  3. The interventions include any type of TCM therapy or western therapy.

  4. The study types include randomized controlled trial (RCT) and observation study.

Exclusion criteria

  1. Studies for discharged patients.

  2. Studies for psychological intervention.

  3. Studies for complications of COVID-19.

Study identification

Two reviewers (RQ and XW) independently assessed all the registered protocols. Any disagreement was resolved by discussion.

Date extraction

Two reviewers (RQ and MZ) independently extracted information. The information included the primary investigators’ name, study type, type of disease, primary sponsor, number of settings, sample size, population’s age, course of treatment, interventions, outcomes, outcome definition/measurement instruments, measurement time frame. Any disagreement was resolved by discussion.

Merging outcomes and grouping under outcome domains

Two researchers (RQ and CZ) merged the overlapping outcomes according to the definition of outcomes independently. If the researchers did not provide definition of outcome, they discussed and achieved consensus if necessary. For example, “PaO2/FiO2”, “oxygenation index”, “oxygen index”, “the difference of PaO2/FiO2 between two groups” were aggregated as “PaO2/FiO2”. Many protocols presented composite outcomes. If definitions were provided, or all of the single outcomes in the composite one can be measured in one test, it was listed in the review. If a single outcome which belongs to a composite outcome was reported by one or more protocols, the composite outcome was removed from the review. But when we conduct Delphi survey in further research, the composite outcome will be list to consult the participants’ opinion.

After the original outcomes were aggregated, two researchers (RQ and CZ) grouped individual outcomes into the appropriate outcome domain together and achieved consensus. The taxonomy of outcome domains were developed by the researchers from COMET initiative [7].

Statistical analysis

The results were analysed by descriptive analysis.

Patient and public involvement

The COVID-19 is highly infectious. For the safety of patients and public, they were not involved in the design or planning of the study.

RESULTS

Characteristics of literature

In this review, a total of 160 protocols from 19 different clinical trials registry platforms were searched. After reading titles and study details, 63 non-relevant or ineligible study protocols were excluded. In the end, 97 eligible study protocols were included from ChiCTR and ClinicalTrials.gov. The searching results and inclusion numbers were shown in Table 1.

View this table:
Table 1 The global registry of COVID-19 related clinical trials searching results and inclusion

In the included protocols, 34 clinical trials were for TCM therapy and 63 clinical trials were for western medicine therapy. All of clinical trials will be conducted in China. These clinical trials include 75 RCTs (53 for western medicine and 22 for TCM medicine) and 22 non-RCTs (10 for western medicine and 12 for TCM medicine). The first registered clinical trial for western medicine was on January 23, 2020, while the first registered clinical trial for TCM medicine was on January 27, 2020. The general characteristics of the included protocols are shown in table 2 and table 3.

View this table:
Table 2 The characteristics of included protocols for TCM clinical trials
View this table:
Table 3 The characteristics of included protocols for western medicine clinical trials

According to the information of primary sponsor, we found that the clinical trials were registered from 13 different provinces of China. Researchers from Hubei province registered more clinical trials (31/97, 31.96%) than researchers from other provinces. The distribution of clinical trials is shown in Figure 1.

Figure 1
Figure 1 The distribution of clinical trials

The list of outcomes

In protocols of TCM clinical trials, the number of primary outcomes are from 1 (13/34, 38.24%) to 13 (1/34, 2.94%), the number of secondary outcomes are from 1 (7/34, 20.59%) to 14 (1/34, 2.94%). 1(1/34, 2.94%) protocol of clinical trial reports other outcomes. For individual clinical trial, the number of outcomes are from 1 (2/34, 5.88%) to 15 (1/34, 2.94%). The number of outcomes in protocols of TCM clinical trials is shown in Figure 2.

Figure 2
Figure 2 The number of outcomes in protocols of TCM clinical trials

In protocols of western medicine clinical trials, the number of primary outcomes are from 1 (39/63, 61.90%) to 10 (1/63, 1.59%), the number of secondary outcomes are from 0 (8/63, 12.70%) to 15(1/63, 1.59%). 5 (5/63, 7.94%) protocols of clinical trials reported other outcomes (the number of outcomes are from 1 to 5). For individual clinical trial, the number of outcomes are from 1 (4/63, 6.35%) to 16 (1/63, 1.59%). The number of outcomes in protocols of western medicine clinical trials is shown in Figure 3.

Figure 3
Figure 3 The number of outcomes in protocols of western medicine clinical trials

After merging and grouping outcomes, there are 76 different outcomes from 16 outcome domains in 34 protocols of TCM clinical trials (table 4). Almost half of outcomes are reported only once (34/76, 44.74%). The most frequently reported outcome is “time of SARS-CoV-2 RNA turns to negative”, which is reported 16 times. Only 3 (3/76, 3.95%) outcomes are reported more than 10 times. Only 27 (27/76, 35.53%) outcomes are provided one or more outcome measurement instruments. Only 10 outcomes are provided one or more measurement time frame. The summary of outcome reporting for protocols of TCM clinical trials is shown in Figure 4.

View this table:
Table 4 Outcomes from protocols of TCM clinical trials
Figure 4
Figure 4 The summary of outcome reporting for protocols of TCM clinical trials

In the 16 outcome domains of protocols of TCM clinical trials, 4 outcome domains (adverse events/effects, hepatobiliary outcomes, mortality/survival, psychiatric outcomes) consisted of only one outcome. These outcomes are reported between 1 and 9 times, and the median outcome reporting time was 6.5. Respiratory, thoracic and mediastinal outcomes have the largest number of outcomes, which includes 17 outcomes; chest imaging is reported more frequently than other outcomes. The number of outcomes in different outcome domains in protocols of TCM clinical trials is shown in Figure 5.

Figure 5
Figure 5 The number of outcomes in different outcome domains in protocols of TCM clinical trials

After merging and grouping, there are 126 different outcomes from 17 outcome domains in 63 protocols of western medicine clinical trials (table 5). Almost half of outcomes are reported only once (62/126, 49.21%). The most frequently reported outcome is “proportion of patients with negative SARS-CoV-2”, which is reported 40 times. Only 11 (11/126, 8.73%) outcomes are reported more than 10 times. Only 27 outcomes are provided one or more outcome measurement instruments. Only 40 (40/126, 31.75%) outcomes are provided one or more measurement time frame. The summary of outcome reporting for protocols of TCM clinical trials is shown in Figure 6.

View this table:
Table 5 Outcomes from protocols of western medicine clinical trials
Figure 6
Figure 6 The summary of outcome reporting for protoclas of western medicine clinical trials

In the 17 outcome domains of protocols of western medicine clinical trials, 5 outcome domains (adverse events/effects, delivery of care, economic, metabolism and nutrition outcomes, mortality/survival) consisted of only one outcome. These outcomes are reported between 1 and 36 times, and the median outcome reporting time is 1. Respiratory, thoracic and mediastinal outcomes included the largest number of outcomes, which includes 31 outcomes; chest imaging is reported more frequently than other outcomes. The number of outcomes in different outcome domains in protocols of western medicine clinical trials is shown in Figure 7.

Figure 7
Figure 7 The number of outcomes in different outcome domains in protocols of western medicine clinical trials

DISCUSSION

This review is the first to evaluate the outcome reporting of protocols of TCM and western medicine clinical trials for treating COVID-19. The results showed variations in the outcome reporting. For outcome measurement instruments/outcome definitions and outcome measurement time, there is also heterogeneity. However, many primary investigators did not provide outcome measurement instruments/outcome definitions or outcome measurement time. It is difficult to predict results of clinical trials now. But it is obvious that these problems may result in the exclusion of some studies from systematic reviews/meta-analyses due to the heterogeneity of outcomes or outcome measurements. It is a waste.

In this review, we find that there are more than 40 duplicated outcomes between protocols of TCM and western medicine clinical trials. No matter for clinical trials of TCM or western medicine, etiological test, chest imaging, respiratory symptoms, temperature, mortality/survival and adverse events are very important. These outcomes are relevant to the prognosis of disease and safety of therapy.

Because of no specific therapy can be used in the treatment of COVID-19, it is necessary and urgent to conduct clinical trials, no matter what the interventions are. We believe that it is important to develop a COS for clinical trials of TCM and western medicine for treating COVID-19, so that the efficacy of different interventions can be compared and merged in systematic review/meta-analysis.

Data Availability

The data is from public database and does not include identifiable patient data.

Contributors

RQ and HS contributed to the study design. XW and MZ conducted searching and extracted data from databases. RQ, CZ, JH, YH, TH contributed to the data analysis. RQ drafted the manuscript. ML, HS, CZ, JC, HS revised the manuscript. All authors read and approved the final manuscript

Funding

This work was supported by the National High-level Personnel of Special Support Program [W02020052].

Competing interests

The authors declare that there is no conflict of interest.

Patient consent

Not required.

Data sharing statement

The data is from public database and does not include identifiable patient data.

References

  1. 1.↵
    China Health Commission of the People’s Republic of China. http://www.nhc.gov.cn/xcs/yqtb/202002/67e6c59a84bd4f07b6ca4a4c5ffabb79.shtml [Accessed 25 Feb 2020].
  2. 2.↵
  3. 3.↵
    China Health Commission of the People’s Republic of China. http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8aefc2/files/b218cfeb1bc54639af227f922bf6b817.pdf [Accessed 25 Feb 2020].
  4. 4.↵
    Shang H, Qiu R. http://www.comet-initiative.org/Studies/Details/1507 [Accessed 20 Feb 2020].
  5. 5.↵
    Huang C. A randomized, open-label, blank-controlled trial for the efficacy and safety of lopinavir-ritonavir and interferon-alpha 2b in hospitalization patients with novel coronavirus pneumonia (COVID-19). Available: http://www.comet-initiative.org/Studies/Details/1507 [Accessed 14 Feb 2020].
  6. 6.↵
    ICMJE. Which trials registries are acceptable to the ICMJE? http://www.icmje.org/about-icmje/faqs/clinical-trials-registration/ [Accessed 14 Feb 2020].
  7. 7.↵
    Dodd S, Clarke M, Becker L, et al. A taxonomy has been developed for outcomes in medical research to help improve knowledge discovery. J Clin Epidemiol 2018, 96:84–92.
    OpenUrlPubMed
  8. 8.
    Zhong N, Song Y, Qiu H, Li Y, Liu X. A prospective comparative study for Xue-Bi-Jing injection in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48768 [Accessed 14 Feb 2020].
  9. 9.
    Huang L. Clinical Controlled Trial for Traditional Chinese Medicine in the treatment of Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48824 [Accessed 14 Feb 2020].
  10. 10.
    Liang T, Wang T, Hao X, et al. Chinese Herbal medicine for Severe nevel coronavirus pneumonia (COVID-19): a Randomized Controlled Trial. http://www.chictr.org.cn/showproj.aspx?proj=48886 [Accessed 14 Feb 2020].
  11. 11.
    Liu Q, Miao Q, Zhang B. A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48911 [Accessed 14 Feb 2020].
  12. 12.
    Xia W, An C, Zhang B. A single arm study for combination of traditional Chinese and Western Medicine in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48913 [Accessed 14 Feb 2020].
  13. 13.
    Wang Y, Li X, Zhang B. Combination of traditional Chinese medicine and western medicine in the treatment of common type novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48904 [Accessed 14 Feb 2020].
  14. 14.
    Li J, Li S. A single arm study for evaluation of integrated traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48884 [Accessed 14 Feb 2020].
  15. 15.
    Zhong N, Zhang B, Li J, et al. A randomized, open-label, blank-controlled trial for Lian-Hua Qing-Wen Capsule/Granule in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48889 [Accessed 14 Feb 2020].
  16. 16.
    Yang Z, Wen M. A Real World Study for the Efficacy and Safety of Large Dose Tanreqing Injection in the Treatment of Patients with Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48881 [Accessed 14 Feb 2020].
  17. 17.
    Zhang J. Traditional Chinese Medicine for Pulmonary Fibrosis, Pulmonary Function and Quality of Life in Patients With Novel Coronavirus Pneumonia (COVID-19) in Convalescent Period: a Randomized Controlled Trial. http://www.chictr.org.cn/showproj.aspx?proj=48931 [Accessed 14 Feb 2020].
  18. 18.
    Zheng C. The effect of shadowboxing for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period. http://www.chictr.org.cn/showproj.aspx?proj=48930 [Accessed 14 Feb 2020].
  19. 19.
    Xia W. The effect of pulmonary rehabilitation for pulmonary function and quality of life in patients with novel coronavirus pneumonia (COVID-19) in rehabilitation period. http://www.chictr.org.cn/showproj.aspx?proj=48929 [Accessed 14 Feb 2020].
  20. 20.
    Xia W. A randomized controlled trial for integrated traditional Chinese medicine and western medicine in the Treatment of Common Type Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48927 [Accessed 14 Feb 2020].
  21. 21.
    Wen C. Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, double-blind, placebo, randomised controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=48860 [Accessed 14 Feb 2020].
  22. 22.
    Xie C. Recommendations of Integrated Traditional Chinese and Western Medicine for Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49014 [Accessed 14 Feb 2020].
  23. 23.
    Xie C. Recommendations of Integrated Traditional Chinese and Western Medicine for Diagnosis and Treatment of Novel Coronavirus Pneumonia (COVID-19) in Sichuan Province. http://www.chictr.org.cn/showproj.aspx?proj=48792 [Accessed 14 Feb 2020].
  24. 24.
    Wen C. Chinese medicine prevention and treatment program for novel coronavirus pneumonia (COVID-19): a perspective, sing-arm trial. http://www.chictr.org.cn/showproj.aspx?proj=49080 [Accessed 14 Feb 2020].
  25. 25.
    Liu Q. An open, prospective, multicenter clinical study for the efficacy and safety of Reduning injection in the treatment of ovel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49104 [Accessed 14 Feb 2020].
  26. 26.
    Wang D, Zhao J. A randomized, open-label, blank-controlled, multicenter trial for Shuang-Huang-Lian oral solution in the treatment of ovel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49051 [Accessed 14 Feb 2020].
  27. 27.
    Zhang Z. An observational study for Xin-Guan-1 formula in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49127 [Accessed 14 Feb 2020].
  28. 28.
    Xiao X. jTreatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection.
  29. 29.
    Zhang N. Effect evaluation and prognosis of Chinese medicine based on Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49287 [Accessed 14 Feb 2020].
  30. 30.
    Mao W. Clinical Study for Traditional Chinese Medicine in the Prevention and Treatment of Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49354 [Accessed 14 Feb 2020].
  31. 31.
    Liu D. A randomized, open, parallel-controlled clinical trial on the efficacy and safety of Jingyebaidu granules in treating novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49301 [Accessed 14 Feb 2020].
  32. 32.
    Huang L, Li Z. The efficacy of traditional chinese medicine on Novel Coronavirus Pneumonia (COVID-19) patients treated in square cabin hospital: a prospective, randomized controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=49408 [Accessed 14 Feb 2020].
  33. 33.
    Lv D. Babaodan Capsule used for the adjuvant treatment of Severe novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49415 [Accessed 14 Feb 2020].
  34. 34.
    Huang T, Fang B, Feng J, et al. A multicenter, randomized, controlled trial for integrated chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19) based on the ‘Truncated Torsion’ strategy. http://www.chictr.org.cn/showproj.aspx?proj=49380 [Accessed 14 Feb 2020].
  35. 35.
    Zhang W. Clinical Study for Traditional Chinese Medicine Combined With Western Medicine in Treatment of Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49422 [Accessed 14 Feb 2020].
  36. 36.
    Zheng X. A multicenter, randomized, open, controlled trial for the efficacy and safety of Shen-Qi Fu-Zheng injection in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49220 [Accessed 14 Feb 2020].
  37. 37.
    Zheng X. A multicenter, randomized, open and controlled trial for the efficacy and safety of Kang-Bing-Du granules in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49138 [Accessed 14 Feb 2020].
  38. 38.
    Zhang Y, Shang J. Traditional Chinese medicine cooperative therapy for patients with novel coronavirus pneumonia (COVID-19): a randomized controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=49452 [Accessed 14 Feb 2020].
  39. 39.
    Wang L. Clinical study for the integration of traditional Chinese and western medicine in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49453 [Accessed 14 Feb 2020].
  40. 40.
    Lu H, Chen X. Clinical Trial for Tanreqing Capsules in the Treatment of Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49425 [Accessed 14 Feb 2020].
  41. 41.
    Zhai X. Clinical Trial for Integrated Chinese and Western Medicine in the Treatment of Children with Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49387 [Accessed 14 Feb 2020].
  42. 42.
    Chen Y. Adjunctive Corticosteroid Therapy for Patients with Severe Novel Coronavirus Pneumonia (COVID-19): a Randomized Controlled Trial. http://www.chictr.org.cn/showproj.aspx?proj=48777 [Accessed 14 Feb 2020].
  43. 43.
    Zhao D. Clinical study for the remedy of M1 macrophages target in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48907 [Accessed 14 Feb 2020].
  44. 44.
    Jiang H. A real-world study for lopinavir/ritonavir (LPV/r) and emtritabine (FTC) / Tenofovir alafenamide Fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48919 [Accessed 14 Feb 2020].
  45. 45.
    Jiang S. Study for the efficacy of chloroquine in patients with novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48968 [Accessed 14 Feb 2020].
  46. 46.
    Wang X, Ke H. A randomised, open, controlled trial for darunavir/cobicistat or Lopinavir/ritonavir combined with thymosin a1 in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48992 [Accessed 14 Feb 2020].
  47. 47.
    Zhao J. A randomized, open-label study to evaluate the efficacy and safety of Lopinavir-Ritonavir in patients with mild novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48991 [Accessed 14 Feb 2020].
  48. 48.
    Gong G. A randomized, open label, parallel controlled trial for evaluating the efficacy of recombinant cytokine gene-derived protein injection in eliminating novel coronavirus in patients with novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48809 [Accessed 14 Feb 2020].
  49. 49.
    Qiu Y. Randomized, open-label, controlled trial for evaluating of the efficacy and safety of Baloxavir Marboxil, Favipiravir, and Lopinavir-Ritonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients. http://www.chictr.org.cn/showproj.aspx?proj=49015 [Accessed 14 Feb 2020].
  50. 50.
    Zhang Z. Therapeutic effect of hydroxychloroquine on novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=48880 [Accessed 14 Feb 2020].
  51. 51.
    Lv Q. A multicenter, randomized, open-label, positive-controlled trial for the efficacy and safety of recombinant cytokine gene-derived protein injection combined with abidole, lopinavir/litonavir in the treatment of novel coronavirus pneumonia (COVID-19) patients. http://www.chictr.org.cn/showproj.aspx?proj=49065 [Accessed 14 Feb 2020].
  52. 52.
    Zhou J. A prospective, single-blind, randomized controlled trial for Ruxolitinib combined with mesenchymal stem cell infusion in the treatment of patients with severe novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49088 [Accessed 14 Feb 2020].
  53. 53.
    Qiu Y. A Randomized, Open-Label, Multi-Centre Clinical Trial Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Confirmed Cases of Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49075 [Accessed 14 Feb 2020].
  54. 54.
    Liu Y. Clinical study for safety and efficacy of Favipiravir in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49042 [Accessed 14 Feb 2020].
  55. 55.
    Chen Y. Comparison of efficacy and safety of three antiviral regimens in patients with mild to moderate novel coronavirus pneumonia (COVID-19): a randomized controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=48782 [Accessed 14 Feb 2020].
  56. 56.
    Shan H. A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in patients with novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49145 [Accessed 14 Feb 2020].
  57. 57.
    Pei B. Safety and efficacy of umbilical cord blood mononuclear cells in the treatment of severe and critically novel coronavirus pneumonia(COVID-19): a randomized controlled clinical trial. http://www.chictr.org.cn/showproj.aspx?proj=41760 [Accessed 14 Feb 2020].
  58. 58.
    Pei B. Safety and efficacy of umbilical cord blood mononuclear cells conditioned medium in the treatment of severe and critically novel coronavirus pneumonia (COVID-19): a randomized controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=49062 [Accessed 14 Feb 2020].
  59. 59.
    Qiu Y. A randomized controlled trial for the efficacy and safety of Baloxavir Marboxil, Favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy. http://www.chictr.org.cn/showproj.aspx?proj=49013 [Accessed 14 Feb 2020].
  60. 60.
    Hu B, Li W. Efficacy and safety of aerosol inhalation of vMIP in the treatment of novel coronavirus pneumonia (COVID-19): a single arm clinical trial. http://www.chictr.org.cn/showproj.aspx?proj=49215 [Accessed 14 Feb 2020].
  61. 61.
    Liu L. Multicenter randomized controlled trial for novel recombinant high-efficiency compound interferon in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49224 [Accessed 14 Feb 2020].
  62. 62.
    Li L, Xu X, Xiang C. Clinical Study for Human Menstrual Blood-Derived Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49146 [Accessed 14 Feb 2020].
  63. 63.
    Wu C. Nasal high-fow preoxygenation assisted fibre-optic bronchoscope intubation in patients with critical novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49074 [Accessed 14 Feb 2020].
  64. 64.
    Du R. A randomized, open-label study to evaluate the efficacy and safety of low-dose corticosteroids in hospitalized patients with novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49086 [Accessed 14 Feb 2020].
  65. 65.
    Qu J. Clinical study of arbidol hydrochloride tablets in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49165 [Accessed 14 Feb 2020].
  66. 66.
    Unclear. Glucocorticoid Therapy for Critically Ill Patients With Severe Acute Respiratory Infections Caused by Noval Coronovirus 2019-nCoV: a Prospective, Randomized Controlled Trial. https://clinicaltrials.gov/ct2/show/record/NCT04244591 [Accessed 14 Feb 2020].
  67. 67.
    Lu H. Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV (DACO-nCoV). https://clinicaltrials.gov/ct2/show/NCT04252274?cond=nCoV&draw=1&rank=6 [Accessed 14 Feb 2020].
  68. 68.
    Qin N. A Prospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia. https://clinicaltrials.gov/ct2/show/NCT04254874?cond=nCoV&draw=2&rank=3 [Accessed 14 Feb 2020].
  69. 69.
    Qin N. A Prospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia. https://clinicaltrials.gov/ct2/show/NCT04255017?cond=nCoV&draw=2&rank=2 [Accessed 14 Feb 2020].
  70. 70.
    Cao B. Mild/Moderate 2019-nCoV Remdesivir RCT. https://clinicaltrials.gov/ct2/show/NCT04252664?cond=nCoV&draw=2&rank=1 [Accessed 14 Feb 2020].
  71. 71.
    Cao B. Severe 2019-nCoV Remdesivir RCT. https://clinicaltrials.gov/ct2/show/NCT04257656?cond=nCoV&draw=2&rank=7 [Accessed 14 Feb 2020].
  72. 72.
    Qu J. Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus. https://clinicaltrials.gov/ct2/show/NCT04260594?cond=nCoV&draw=2&rank=6 [Accessed 14 Feb 2020].
  73. 73.
    Qin N. A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia. https://clinicaltrials.gov/ct2/show/NCT04261270?cond=nCoV&draw=2&rank=5 [Accessed 14 Feb 2020].
  74. 74.
    Li T. The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia. https://clinicaltrials.gov/ct2/show/NCT04261426?cond=nCoV&draw=2&rank=2 [Accessed 14 Feb 2020].
  75. 75.
    Lu H. Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV). https://clinicaltrials.gov/ct2/show/NCT04261517?cond=nCoV&draw=3&rank=13 [Accessed 14 Feb 2020].
  76. 76.
    Zhang Z. Efficacy of therapeutic effects of hydroxycholoroquine in novel coronavirus pneumonia (COVID-19) patients(randomized open-label control clinical trial). http://www.chictr.org.cn/showproj.aspx?proj=49317 [Accessed 14 Feb 2020].
  77. 77.
    Xia J. Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study. http://www.chictr.org.cn/showproj.aspx?proj=49263 [Accessed 14 Feb 2020].
  78. 78.
    Ning Q, Han M. A randomized, parallel controlled trial for the efficacy and safety of Sodium Aescinate Injection in the treatment of patients with pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49297 [Accessed 14 Feb 2020].
  79. 79.
    Qin N. The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia. https://clinicaltrials.gov/ct2/show/NCT04263402?id=NCT04263402&draw=2&rank=1 [Accessed 14 Feb 2020].
  80. 80.
    Qiu Y. Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection. https://clinicaltrials.gov/ct2/show/NCT04261907?id=NCT04261907&draw=2&rank=1 [Accessed 14 Feb 2020].
  81. 81.
    Li L. The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection (ELACOI). https://clinicaltrials.gov/ct2/show/NCT04252885?id=NCT04252885&draw=2&rank=1 [Accessed 14 Feb 2020].
  82. 82.
    Shi L, Wang F. Patients Infected With 2019 Novel Coronavirus. https://clinicaltrials.gov/ct2/show/NCT04252118?id=NCT04252118&draw=2&rank=1 [Accessed 14 Feb 2020].
  83. 83.
  84. 84.
  85. 85.
  86. 86.
    Zhang Z. Clinical study of nebulized Xiyanping injection in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49222 [Accessed 14 Feb 2020].
  87. 87.
    Liu Z. Convalescent plasma for the treatment of severe novel coronavirus pneumonia (COVID-19): a prospective randomized controlled trial. http://www.chictr.org.cn/showproj.aspx?proj=49081 [Accessed 14 Feb 2020].
  88. 88.
    Kang Y. Cohort Study of Novel Coronavirus Pneumonia (COVID-19) Critical Ill Patients. http://www.chictr.org.cn/showproj.aspx?proj=49295 [Accessed 14 Feb 2020].
  89. 89.
    Hu P. A multicenter, randomized, open label, controlled trial for the efficacy and safety of ASC09/ Ritonavir compound tablets and Lopinavir/ Ritonavir (Kaletra) and Arbidol tablets in the treatm ent of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49352 [Accessed 14 Feb 2020].
  90. 90.
    Mao H. A study for the efficacy of hydroxychloroquine for mild and moderate COVID-19 infectious diseases. http://www.chictr.org.cn/showproj.aspx?proj=49369 [Accessed 14 Feb 2020].
  91. 91.
    Huang W. Clinical study on the safety and effectiveness of Hydroxychloroquine Sulfate tablets in the treatment of patients with novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49400 [Accessed 14 Feb 2020].
  92. 92.
    Huang W. Clinical study for the effect and safety of hydroxychloroquine sulfate tablets in the treatment of patients with severe novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49404 [Accessed 14 Feb 2020].
  93. 93.
    Xu X. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49409 [Accessed 14 Feb 2020].
  94. 94.
    Lin J. A randomized, open, controlled trial for diammonium glycyrrhizinate enteric-coated capsules combined with vitamin C tablets in the treatment of common novel coronavirus pneumonia (COVID-19) in the basic of clinical standard antiviral treatment to evaluate the safety and efficiency. http://www.chictr.org.cn/showproj.aspx?proj=49 [Accessed 14 Feb 2020].
  95. 95.
    Huang X. A randomized, open-label, blank-controlled, multicenter trial for Polyinosinic-Polycytidylic Acid Injection in the treatment of novel coronavirus pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49342 [Accessed 14 Feb 2020].
  96. 96.
    Wu W. Clinical Application of ECMO in the Treatment of Patients with Very Serious Respiratory Failure due to novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49178 [Accessed 14 Feb 2020].
  97. 97.
    Xia J. Immunomodulatory Therapy for Severe Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49161 [Accessed 14 Feb 2020].
  98. 98.
    Xu C. Clinical Study for Anti-aging Active Freeze-dried Powder Granules in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49355 [Accessed 14 Feb 2020].
  99. 99.
    Xu C. Clinical Study for Umbilical Cord Blood Mononuclear Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49374 [Accessed 14 Feb 2020].
  100. 100.
    Xu C. Clinical Study for Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49389 [Accessed 14 Feb 2020].
  101. 101.
    Xu C. Clinical Study of Cord Blood NK Cells Combined with Cord Blood Mesenchymal Stem Cells in the Treatment of Acute Novel Coronavirus Pneumonia (COVID-19). http://www.chictr.org.cn/showproj.aspx?proj=49384 [Accessed 14 Feb 2020].
  102. 102.
  103. 103.
Back to top
Posted March 08, 2020.
Download PDF
Data/Code
Email
Outcome reporting from protocols of clinical trials of Coronavirus Disease 2019 (COVID-19): a review
Ruijin Qiu, Xuxu Wei, Mengzhu Zhao, Changming Zhong, Chen Zhao, Jiayuan Hu, Min Li, Ya Huang, Songjie Han, Tianmai He, Jing Chen, Hongcai Shang
medRxiv 2020.03.04.20031401; doi: https://doi.org/10.1101/2020.03.04.20031401
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area